Ziad Kawar

Title: Ziad Kawar: Innovator in Anti-P-Selectin Antibodies

Introduction

Ziad Kawar is a notable inventor based in Oklahoma City, OK (US). He has made significant contributions to the field of medical research, particularly in the development of treatments for sickle cell disease and other inflammatory conditions. With a total of 4 patents, his work has the potential to impact many lives.

Latest Patents

Kawar's latest patents focus on methods of treating sickle cell disease using anti-P-selectin antibodies. The first patent features antibodies that recognize P-selectin, preventing it from binding to its receptor. These antibodies can be utilized to treat various conditions, including sickle cell disease, pain crises associated with it, deep vein thrombosis, asthma, rheumatoid arthritis, psoriasis, and ischemia reperfusion injury. The second patent discloses antibodies that specifically bind to P-selectin, blocking the binding of PSGL-1 and causing the dissociation of preformed P-selectin/PSGL-1 complexes. This innovative approach highlights a previously unrecognized antibody binding domain of P-selectin, which can be targeted for therapeutic purposes.

Career Highlights

Throughout his career, Ziad Kawar has worked with prominent organizations such as Selexys Pharmaceuticals Corporation and the Oklahoma Medical Research Foundation. His experience in these institutions has allowed him to advance his research and contribute to the development of groundbreaking medical treatments.

Collaborations

Kawar has collaborated with esteemed colleagues, including Rodger P. McEver and Richard Alvarez. These partnerships have further enriched his research and innovation in the field of medical science.

Conclusion

Ziad Kawar's work in developing anti-P-selectin antibodies represents a significant advancement in the treatment of inflammatory and thrombotic conditions. His contributions to medical research continue to pave the way for innovative therapies that can improve patient outcomes.